Posted by Michael Wonder on 07 Aug 2019
Ortho Dermatologics announces U.S. FDA filing acceptance for IDP-123 treatment for acne vulgaris in lotion form
7 August 2019 - Bausch Health and its dermatology business, Ortho Dermatologics, today announced that the U.S. FDA has accepted the new drug application for IDP-123 (tazarotene 0.045%) lotion with a PDUFA action date of 22 December 2019.
If approved, IDP-123 will be the first tazarotene acne treatment available in a lotion form.
